Provexis PLC
PXS
Company Profile
Business description
Provexis PLC is engaged in developing, licensing, and selling the proprietary, scientifically backed Fruitflow heart-health functional food ingredient for the globally functional food sector. The extract is available in two formats: a syrup and a powder, and it can be included in a broad range of food, beverage, and dietary supplement formats.
Contact
2 Blagrave Street
I Ford
ReadingBerkshireRG1 1AZ
GBRT: +44 7490391888
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2027
Employees
3
Stocks News & Analysis
stocks
Meta earnings: Early look at Muse adoption impresses investors
We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.
stocks
Tesla earnings: Shares fall on slower deliveries growth outlook; Raising valuation
Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,905.80 | 11.30 | -0.13% |
| CAC 40 | 7,811.26 | 110.42 | -1.39% |
| DAX 40 | 25,371.75 | 273.29 | -1.07% |
| Dow JONES (US) | 52,867.98 | 11.89 | 0.02% |
| FTSE 100 | 10,725.03 | 27.85 | -0.26% |
| HKSE | 23,076.96 | 142.28 | 0.62% |
| NASDAQ | 26,008.86 | 694.00 | -2.60% |
| Nikkei 225 | 62,527.74 | 380.10 | -0.60% |
| NZX 50 Index | 13,733.93 | 12.91 | -0.09% |
| S&P 500 | 7,663.43 | 93.74 | -1.21% |
| S&P/ASX 200 | 8,795.20 | 2.00 | 0.02% |
| SSE Composite Index | 3,641.59 | 16.43 | -0.45% |